stockrow
Saturday 7 November 2026
Export OCGN’s income statement to Excel — free account
Ocugen, Inc.
OCGN Healthcare Biotechnology
Ocugen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.4 million, up 8.83% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +84.9%
- Free cash flow
- −22.2%
- Total debt
- −93.7%
Quarter to September 2026, against a year earlier
0.93
0.11
+13.41%
Follow OCGN
Alert me
Ocugen, Inc. (OCGN) P/E ratio
Ocugen, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 145× (October 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
Low 0.0×
High 145×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| DTIL Precision BioSciences, Inc. compare | n/m |
| OCGN Ocugen, Inc. | n/m |
| IPSC Century Therapeutics, Inc. compare | n/m |
| VOGX Vogenx Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)